Henry CE - Search Results

1

A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles.

Lu M , Henry CE , Lai H , Khine YY , Ford CE , Stenzel MH . Lu M , et al. Among authors: henry ce. Biomater Sci. 2019 Mar 26;7(4):1652-1660. doi: 10.1039/c8bm01326h. Biomater Sci. 2019. PMID: 30724288

2

The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer.

Ford CE, Punnia-Moorthy G, Henry CE, Llamosas E, Nixdorf S, Olivier J, Caduff R, Ward RL, Heinzelmann-Schwarz V. Ford CE, et al. Among authors: henry ce. Gynecol Oncol. 2014 Aug;134(2):338-45. doi: 10.1016/j.ygyno.2014.06.004. Epub 2014 Jun 10. Gynecol Oncol. 2014. PMID: 24924122

3

Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling.

Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D, Daniels B, Ward RL, Ford CE. Henry C, et al. J Cancer Res Clin Oncol. 2015 Feb;141(2):243-54. doi: 10.1007/s00432-014-1824-y. Epub 2014 Sep 11. J Cancer Res Clin Oncol. 2015. PMID: 25209439

4

Wnt signalling in gynaecological cancers: A future target for personalised medicine?

Ford CE, Henry C, Llamosas E, Djordjevic A, Hacker N. Ford CE, et al. Among authors: henry c. Gynecol Oncol. 2016 Feb;140(2):345-51. doi: 10.1016/j.ygyno.2015.09.085. Epub 2015 Sep 30. Gynecol Oncol. 2016. PMID: 26432042 Review.

5

Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.

Henry C, Llamosas E, Knipprath-Meszaros A, Schoetzau A, Obermann E, Fuenfschilling M, Caduff R, Fink D, Hacker N, Ward R, Heinzelmann-Schwarz V, Ford C. Henry C, et al. Oncotarget. 2015 Nov 24;6(37):40310-26. doi: 10.18632/oncotarget.5643. Oncotarget. 2015. PMID: 26515598 Free PMC article.

6

Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer.

Henry CE, Llamosas E, Djordjevic A, Hacker NF, Ford CE. Henry CE, et al. Oncogenesis. 2016 May 30;5(5):e226. doi: 10.1038/oncsis.2016.32. Oncogenesis. 2016. PMID: 27239958 Free PMC article.

7

Validation of specificity of antibodies for immunohistochemistry: the case of ROR2.

Ma SS, Henry CE, Llamosas E, Higgins R, Daniels B, Hesson LB, Hawkins NJ, Ward RL, Ford CE. Ma SS, et al. Among authors: henry ce. Virchows Arch. 2017 Jan;470(1):99-108. doi: 10.1007/s00428-016-2019-5. Epub 2016 Sep 8. Virchows Arch. 2017. PMID: 27631337

8

Erratum to: Validation of specificity of antibodies for immunohistochemistry: the case of ROR2.

Ma SS, Henry CE, Llamosas E, Higgins R, Daniels B, Hesson LB, Hawkins NJ, Ward RL, Ford CE. Ma SS, et al. Among authors: henry ce. Virchows Arch. 2016 Dec;469(6):717. doi: 10.1007/s00428-016-2036-4. Epub 2016 Oct 29. Virchows Arch. 2016. PMID: 27796585 No abstract available.

9

Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer.

Henry CE, Emmanuel C, Lambie N, Loo C, Kan B, Kennedy CJ, de Fazio A, Hacker NF, Ford CE. Henry CE, et al. Transl Oncol. 2017 Jun;10(3):346-356. doi: 10.1016/j.tranon.2017.01.014. Epub 2017 Mar 23. Transl Oncol. 2017. PMID: 28342318 Free PMC article.

10

Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis.

Henry C, Hacker N, Ford C. Henry C, et al. Oncotarget. 2017 Nov 20;8(68):112727-112738. doi: 10.18632/oncotarget.22559. eCollection 2017 Dec 22. Oncotarget. 2017. PMID: 29348860 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters